Evaluate the function of SEMA4A in ECRS pathogenesis via cross-talk among neural network and immunoreaction

• Project/Area Number: 16H06958
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Otorhinolaryngology
• Research Institution: Osaka University
• Principal Investigator: Tsuda Takeshi 大阪大学, 医学部附属病院, 医員 (00778631)
• Project Period (FY): 2016-08-26 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000); Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: SEMA4A / 好酸球性副鼻腔炎 / 免疫学 / 臨床 / アレルギー・ぜんそく

Outline of Final Research Achievements

Serum SEMA4A levels were significantly higher in patients with ECRS than in those with other diseases. Serum SEMA4A levels were not correlated with clinical disease activity of ECRS. There were no significant differences in in vivo peritoneal migration, in vitro degranulation between eosinophils derived from Wild type (WT) and SEMA4A deficient mice.
BMDEo from SEMA4A deficient mice may produce larger amount of CXCL12 than those from WT mice. Recombinant SEMA4A enhanced the production of MMP-1 from Human nasal epithelial cells (HNEpC).